Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 9/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SELL | P14151 | 3/20 | 0.47 |
| ▸ | SELE | P16581 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20676875 | 1.00 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676876 | 1.00 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676797 | 1.00 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676905 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676906 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676902 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676857 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676904 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676901 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE | |
| SCHEMBL20676775 | 0.96 | APP (0.51) | APPSELPEPHX2SELLSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | KEIO UNIVERSITY (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3434684-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | Keio University (JP) | 2019-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207798-A1 | COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION | CD4, NFATC1, PBK | APP 1988/4885SELP 776/4885EPHX2 2525/4885 |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | CD4, NFATC1, PBK | APP 2064/4885SELP 758/4885EPHX2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.